Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03035708 · ClinicalTrials.gov registry record · Phase 1
Human Laboratory Study of Varenicline for Alcohol Use Disorder
A Phase 1 study of Alcohol Use Disorder, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT03035708: Completed Phase 1 study of Alcohol Use Disorder, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT03035708 is a Phase 1 study of Alcohol Use Disorder that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 47 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03035708, a Phase 1 study of Alcohol Use Disorder, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a double-blind, randomized, placebo-controlled, parallel group, two-site study designed to assess the effects of varenicline as compared with placebo on responses to in vivo alcohol cue exposure in the human laboratory setting.
Primary Outcome
The primary outcome is cue-elicited alcohol craving, operationalized as the difference in Visual Analog Scale (VAS) craving for alcohol when exposed to an alcohol cue minus the VAS craving for alcohol when exposed to a water cue. The VAS has a minimum value of 0 and maximum value of 20; higher scores indicate more craving (a worse outcome).
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Placebo oral capsule
Study Locations (2)
Connecticut
- Yale University School of Medicine - New Haven
Rhode Island
- Brown University - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-07-07 |
| Phase | Phase 1 |
What the finished NCT03035708 record still lists
NCT03035708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Varenicline is the first listed.
NCT03035708 reports a single indexed study location in Connecticut, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT03035708 about?
NCT03035708 is a clinical study titled "Human Laboratory Study of Varenicline for Alcohol Use Disorder". This study is a double-blind, randomized, placebo-controlled, parallel group, two-site study designed to assess the effects of varenicline as compared with placebo on responses to in vivo alcohol cue exposure in the human laboratory setting.
What is the current status of trial NCT03035708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-05-01. Estimated completion is 2018-07-07.
What conditions does trial NCT03035708 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT03035708?
The interventions under investigation include: Varenicline (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03035708?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03035708 being conducted?
This trial has 2 study locations across Connecticut, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03035708's enrollment target sits among peer trials
47 131st of 184 higher than 54 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI